Publications

5677 Results

A Randomized Phase II/III Study Of “Novel Therapeutics” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML), Age 60 or Older: A Report of the Comparison of Azacitidine and Nivolumab to Azacitidine: SWOG S1612

Authors
S Assouline;L Michaelis;M Othus;A Hay;R Walter;M Jacoby;M Schroeder;G Uy;L Law;F Cheema;K Sweet;A Asch;J Liu;A Moseley;T Maher;L Kingsbury;M Fang;J Radich;R Little;H Erba
Journal / Conference
Leukemia and Lymphoma Feb;64(2):473-477
Year
2023
Research Committee(s)
Leukemia
PMID
PMID36517990
Study Number(s)
S1612

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

Authors
E Rodler;Sharma;W Barlow;J Gralow;S Puhalla;C Anders;L Goldstein;D Tripathy;U Brown-Glaberman;T Huynh;C Szyarto;A Godwin;H Pathak;E Swisher;M Radke;K Timms;D Lew;J Miao;L Pusztai;D Hayes;G Hortobagyi
Journal / Conference
Lancet Oncology Feb;24(2):162-174
Year
2023
Research Committee(s)
Breast
PMID
PMID36623515
PMC
PMC9924094
Study Number(s)
S1416

Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in the SWOG S8814 trial

Authors
C Speers;WF Symmans;W Barlow;A Trevarton;S The;L Du;J Rae;S Shak;R Baehner;P Sharma;L Pusztai;G Hortobagyi;D Hayes;K Albain;A Godwin;A Thompson
Journal / Conference
Journal of Clinical Oncology Apr 1;41(10):1841-1848
Year
2023
Research Committee(s)
Breast
PMID
PMID36649570
PMC
PMC10082279
Study Number(s)
SWOG-8814

Quality-of-life outcomes and risk-prediction for advanced lung cancer treated with Nivolumab/Ipilimumab vs Nivolumab

Authors
J Unger;L Qian;M Redman;S Tavernier;L Minasian;E Sigal;V Papadimitrakopoulou;M LeBlanc;C Cleeland;S Dzingle;T Summers;H Chao;S Madhusudhana;L Villaruz;J Crawford;JE Gray;KL Kelly;DR Gandara;L Bazhenova;RS Herbst;S Gettinger;C Moinpour
Journal / Conference
Journal of the National Cancer Institute Apr 11;115(4):437-446
Year
2023
Research Committee(s)
Lung
PMID
PMID36625510
PMC
PMC10086628
Study Number(s)
S1400I

Tumor-derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer (SWOG S0500)

Authors
A Nanou;J Miao;F Coumans;E Dolce;E Darga;W Barlow;J Smerage;G Hortobagyi;L Terstappen;D Hayes
Journal / Conference
JCO Precision Oncology Jan;7:e2200372. doi: 10.1200/PO.22.00372.
Year
2023
Research Committee(s)
Breast
PMID
PMID36634296
PMC
PMC9928629
Study Number(s)
S0500

Associations of Inflammatory Biomarkers with Survival Among Patients with Stage III Colon Cancer (CALGB/SWOG 80702 [Alliance])

Authors
E Cheng;Q Shi;A Shields;A Nixon;R Nader;A Shergill;C Ma;K Guthrie;F Couture;P Kuebler;P Kumar;D Lewis;B Tan;S Krishnamurthi;K Ng;E O'Reilly;J Brown;P Philip;B Caan;E Feliciano;J Meyerhardt
Journal / Conference
JAMA Oncology Mar 1;9(3):404-413
Year
2023
Research Committee(s)
Gastrointestinal
PMID
PMID36701146
PMC
PMC9880869
Study Number(s)
CTSU/C80702

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer: SWOG S2107 (NCT05308446)

Authors
V Morris;K Guthrie;S Kopetz;R Breakstone;T Karasic;ZI Hu;S Colby;M Fakih;S Gholami;P Gold;PA Philip
Journal / Conference
J Clin Oncol 41, 2023 (suppl 4; abstr TPS265); ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA)
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S2107

Thymidine Kinase Activity Levels in Serum Can Identify HR+ Metastatic Breast Cancer Patients with a Low Risk of Early Progression (SWOG S0226)

Authors
M Bergqvist;A Nordmark;A Williams;C Paoletti;W Barlow;E Cobain;R Mehta;J Gralow;G Hortobagyi;K Albain;L Pusztai;P Sharma;A Godwin;A Thompson;D Hayes;J Rae
Journal / Conference
Biomarkers Jan 29:1-10
Year
2023
Research Committee(s)
Breast
PMID
PMID36647745
PMC
PMC10681159
Study Number(s)
S0226

Neoadjuvant versus adjuvant pembrolizumab for resectable stage III-IV melanoma

Authors
SP Patel;M Othus;Y Chen;GP Wright;K Yost;J Hyngstrom;S Hu-Lieskovan;C Lao;L Fecher;T-G Truong;J Eisenstein;S Chandra;J Sosman;K Kendra;R Wu;C Devoe;G Deutsch;A Hedge;M Khalil;A Reese;M Ross;A Poklepovic;G Phan;A Onitilo;D Gokalp Yasar;B Powers;G Doolittle;G In;N Kokot;G Gibney;M Atkins;M Shaheen;J Warneke;A Ikeguchi;J Eugenio Najero;B Chmielowski;J Crompton;J Floyd;E Hsueh;K Margolin;W Chow;K Grossmann;E Dietrich;V Prieto;M Lowe;E Buchbinder;J Kirkwood;L Korde;J Moon;E Sharon;V Sondak;A Ribas
Journal / Conference
New England Journal of Medicine Mar 2;388(9):813-823
Year
2023
Research Committee(s)
Melanoma
PMID
PMID36856617
PMC
PMC10410527
Study Number(s)
S1801

Long Non-coding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia

Authors
J Farrar;J Smith;M Othus;B Huang;Y Wang;R Ries;T Hylkema;E Pogosova-Agadjanyan;A Leonti;T Shaw;T Triche;A Gamis;R Aplenc;E Kolb;X Ma;D Stirewalt;T Alonzo;S Meshinchi
Journal / Conference
Journal of Clinical Oncology Jun 1;41(16):2949-2962
Year
2023
Research Committee(s)
Leukemia
PMID
PMID36795987
PMC
PMC10414715
Study Number(s)
S0106, S0112, SWOG-9031, SWOG-9333